Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM is a phase 3 interventional study registered as NCT05118776, led by Ascletis Pharmaceuticals, and active but no longer recruiting on the registry. Official title: A Phase III Randomised, Double-blind, Placebo-controlled, Multi-centre Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma. Planned enrolment is 136 participants (actual). The study started in 2022-01-21 and primary completion is expected in 2025-06. No results have been posted on ClinicalTrials.gov.